

COVID-19

11TH OCTOBER 2021 FORTNIGHTLY EDITION

Science & Technology Efforts in India VOL. IV | ISSUE 12

 $\mathbf{COV} \mathbf{D} - 19$

In the face of adversity we have a choice - stay updated with scientific facts

DISCLAIMER

Contents in this e-Newsletter are for information purposes only and have been made available in public by the relevant department/organisation.

In case of any variance between what has been stated and that contained in the relevant document, the latter shall prevail.

Unless otherwise specifically stated, the information contained herein is made available to the public for information purposes only.

Although we have made the best effort to keep the information updated, the accuracy, completeness or adequacy of information will depend on what is made available by the third party or the same being up-to-date.

This will depend on the availability of the same. The e-Newsletter is continuously evolving and the aggregation of information is an unceasing process.

The process requires the co-operation of and synergy with all stakeholders.

PREFACE

G reetings from the desk of e-Newsletter – *COVID-19*: Science & Technology Efforts in India – on COVID-19, highlighting scientific, technological, and innovative efforts and research supports to mitigate and minimise the pandemic. Now we are armed with various weapons in our armour, like vaccines, therapeutics, immune boosters, and so on, to tackle the situation.

In the meantime, we continue compiling new information every fortnight on the pandemic to continue sensitising our readers about COVID-related latest developments. The aim is to inform the readers and strengthen the usefulness of the information. This edition contains compilation and coverage of information related to industry collaborations, significant research outputs, COVID communication, resources and outreach, along with fact-check questionnaires.

The collective strength of the nation and the service spirit of the frontline workers have ensured that we are coming out of the perilous situation. This pandemic has taught us to practice hand and respiratory hygiene. Till we hit ground zero on the transmission of the disease, we strictly need to adhere to additional COVID appropriate behaviour. We wish an engaging reading to our audiences across all strata of the society and look forward to their suggestions and feedback at covidnewsletter@vigyanprasar.gov.in.

11 October 2021

Vigyan Prasar

New Delhi

The older issues of e-newsletter are available in the Archival Section at https://vigyanprasar.gov.in/covid19-newsletters/

	DEX
TOPICS	PAGE NO.
I. Efforts Impacting COVID Mitigation	01-04
2. Research Supports	05-08
3. Industry Collaborations	09-10
4. COVID Resources and Outreach	11-20
5. COVID Fact-checks	21-38

EFFORTS IMPACTING COVID MITIGATION

The efforts made by various agencies, apex bodies, domain institutions, and so on, who are working in the STI ecosystem towards meeting the requirements posed due to the pandemic are compiled here for the consumption and benefit of the general public. These efforts are presented here in terms of deliverables, outputs, technologies, products, services, etc., which are impactful and bring in STI elements in the activities and initiatives.

SECTION GUIDELINES

- ICMR invites expression of interest (EOI) for participation in 'Indian Clinical Trial & Education Network (INTENT)'
- THSTI, Faridabad collaborates with Nanogen Pharmaceutical Biotechnology, Vietnam, for developing a new vaccine against COVID-19
- CIAB utilises Agri-biomass in fighting COVID-19
- CCMB study detects gene suppression in COVID-19 patients as the reason for loss of taste and sense of smell
- ICMR invites expression of interest for validation of rapid antigen detection assays for COVID-19

ICMR invites expression of interest (EOI) for participation in 'Indian Clinical Trial & Education Network (INTENT)'

Indian Council of Medical Research (ICMR) calls for expression of interest (EOI) for participation in 'Indian Clinical Trial & Education Network (INTENT)'. All government medical colleges/ institutes, private medical colleges/institutes, hospitals with experience of conducting RCTs and ICMR institutes can apply for advanced centre for clinical trial.

INTENT envisages providing evidence-based, cost effective, scientifically sound, and culturally appropriate solutions to diseases and health issues of national and/or regional importance. It will provide a single platform to conduct a range of randomised clinical trials (RCT) that will enable harmonisation of trial methods, pooling of results and timely completion of the projects, along with an inclusive representation of the diverse Indian communities. Additionally, this network will be at the forefront for capacity building of a pool of health researchers across the country. The trainees will acquire requisite skills to plan and conduct RCTs and to analyse and disseminate the results that could inform policy and practice.



Structure of Indian Clinical Trial & Education Network

Last date to apply: 15 October 2021

Contact info

Dr Aparna Mukherjee intent.icmr@gmail.com

Website link:

https://www.icmr.gov.in/pdf/tender/Eol_INTENT.pdf

THSTI, Faridabad collaborates with Nanogen Pharmaceutical Biotechnology, Vietnam, for developing a new vaccine against COVID-19

After helping Indian companies for clinical trials/development of vaccines for COVID-19 including Dr Reddy's (Sputnik), Zydus Cadilla (DNA vaccine), and Biological E, Translational Health Science and Technology Institute (THSTI), Department of Biotechnology, M/o Science & Technology, Government of India has entered into a research collaboration with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese pharmaceutical company, which is developing a new





vaccine for COVID-19. His Excellency Pham Sanh Chau, the Ambassador of Vietnam to India, led a team that visited THSTI on 23 September 2021, to sign MoU between THSTI and the Nanogen Pharmaceutical Biotechnology JSC. THSTI has been at the forefront of research for COVID-19 vaccines.



Dr Renu Swarup, Secretary, Department of Biotechnology congratulated THSTI for leveraging its expertise and

facilities not only for India but also globally. She applauded the scientists and appreciated their efforts in developing vaccines and therapeutics.

Website link:

https://dbtindia.gov.in/pressrelease/translational-health-science-and-technology-institute-thsti-do-biotechnology-mo-science

CIAB utilises Agri-biomass in fighting COVID-19

Center of Innovative and Applied Bioprocessing (CIAB), an autonomous institute of the Department of Biotechnology, is working towards antiviral efficacy. However, faculties at CIAB have taken up this challenge to address this pandemic via converting agriproducts into therapeutics. The following research activities have been initiated, which apply multiple research expertise including chemistry, chemical engineering,



biotechnology, molecular biology, and nanotechnology available at DBT-CIAB.

Research activity I - Polypyrrollic photosensitisers and their nanoformulations for antiviral photodynamic therapy

Research activity 2 - Natural garlic essential oil as an ACE2 protein inhibitor for preventing SARS-CoV-2 invasion

Products of the proposed research outcome are expected to be biocompatible, low cost and scalable. Most importantly, the research objectives proposed have deliverables planned to be completed in less than a year's time. The potential antiviral molecules which are identified in this work will be tested for their ability to act against SARS-CoV-2 in collaboration with the Regional Centre for Biotechnology, Faridabad.

Contact info:

ceo@ciab.res.in

Website link:

http://www.ciab.res.in/Documents/Misc/COVID19CIABactivity24.pdf

CCMB study detects gene suppression in COVID-19 patients as the reason for loss of taste and sense of smell

Researchers from the Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) have unlocked the mystery behind the loss of sense of smell and taste, the two-key symptoms that went a long way in identifying the tell-tale signs of COVID-19 positive patients' status.



At the height of both waves of the COVID-19 pandemic, health care workers and scientists were keenly looking at two key clinical symptoms: a loss of the olfactory (smell) and gustation (taste) receptors. The loss of both receptors, and their associated pathways, were a major correlate of the COVID-19 infection.

The researchers have indicated that genes associated with the olfactory and gustation functions become suppressed, causing COVID-19 positive patients to lose their ability to smell and taste. The study found that genes associated with crucial body functions, including those of the respiratory system, the heart, the endocrine system and the nervous system, were also suppressed or lowered.

The CCMB study revealed that the SARS-CoV-2 virus tended to react with genes leading to 'downregulation' or 'upregulation' of some of them. While downregulation is the process by which a cell decreases the quantity of a cellular component, such as RNA or protein, in response to an external stimulus, upregulation is an increase in these components. Both downregulation and upregulation disrupt the functioning of the body. The study revealed that while upregulation was found in the immune response genes and resulted in an increase in the amount of inflammation, downregulation was witnessed in genes responsible for neurotransmission, neurological, cardiovascular, and muscular contraction.

The study involved investigating the genetic changes in 36 COVID-19 patients, ranging from those needing critical and intensive care intervention to those treated at the ward-level, during the pandemic's first wave. Five COVID-19 negative samples were also analysed. Researchers said that studies such as theirs were useful for scientists to not only compare host responses in the current and subsequent waves of the pandemic but also to come up with therapeutic solutions.

Website link:

https://www.csir.res.in/sites/default/files/26%20To%2030%20September%202021. pdf

ICMR invites expression of interest for validation of rapid antigen detection assays for COVID-19

ICMR invites applications for validation of rapid antigen detection tests for COVID-19 from all manufacturers who have developed rapid antigen test (RAT) kits. Requirements for validations are based on various categories, like first-time validation, revalidation, and validation with alternate sample types. The gold standard RT-PCR diagnostic test for COVID-19 has limitations in terms of widespread availability. In view of this, there is urgent requirement for reliable and convenient rapid point of care antigen detection assays with high sensitivity and specificity. Such assays could be used as potential diagnostic tests in all possible public and private health care settings and made available for mass testing.

Deadline: Open till next announcement

Contact info:

guptanivedita.hq@icmr.gov.in, drneetu.vijay@icmr.gov.in

Website link:

https://www.icmr.gov.in/pdf/tender/Revised_EOI_for_Ag_kit_validation_I308202I.pdf

RESEARCH SUPPORTS

The scientific approach has driven the ways the country is mitigating the pandemic. Here is an effort to sew up the significant contributions made by STI communities to humankind. The information is most suitable for the research fraternity, for whom the contact information is also provided to communicate further and up-skill the research.

SECTION GUIDELINES

- Clinical characteristics, outcomes, and mortality in pregnant women with COVID-19 in Maharashtra, India: Study by ICMR
- NCBS-TIFR studies strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors
- IIT Bombay studies severity of COVID-19 infection

Clinical characteristics, outcomes, and mortality in pregnant women with COVID-19 in Maharashtra, India: Study by ICMR

An ICMR study has found that coronavirus may infect a higher proportion of pregnant women leading to moderate-to-severe diseases. The most common complications were pre-term delivery and hypertensive disorders in pregnancy. The analysis was based on the data from the PregCovid registry, a study of pregnant women and women in the post-partum period with a confirmed diagnosis of COVID-19.

The PregCovid registry prospectively collects information in near-real time on pregnant and post-partum women with a laboratory-confirmed diagnosis of SARS-CoV-2 from 19 medical colleges across Maharashtra, India. The data of 4203 pregnant women were collected during the first wave of the COVID-19 pandemic (March 2020-January 2021) and then it was analysed. Out of 4203 data collected, there were 3213 live births, 77 miscarriages and 834 undelivered pregnancies. The most common complication was preterm delivery

Parameters	n (%)
Pregnancy outcomes (n=3369)	
Total delivered	3250
Vaginal deliveries	1719 (52.9)
Caesarean section	1531 (47.1)
Total birth	3312
Preterm birth	567 (17.1)
Stillbirth	99 (2.9)
Miscarriage	77 (1.8)
Ectopic pregnancy	15 (0.4)
Medical termination of pregnancy	27 (0.6)
Pregnancy complications (n=3250)	
Preterm delivery	528 (16.3)
PROM/PPROM	135 (4.2)
Hypertensive disorders of pregnancy	328 (10.1)
Gestational hypertension	97 (3.0)
Precclampsia	191 (5.9)
Eclampsia	40 (1.2)
Gestational diabetes mellitus	42 (1.3)
Oligohydramnios	166 (5.1)
Polyhydramnios	15 (0.5)
Foetal growth restriction	41 (1.3)
Congenital malformations in foctus	11 (0.3)
Placenta praevia	23 (0.7)
Placental abruption	14 (0.4)
APH	16 (0,5)
РРН	27 (0.8)
Cholestasis of pregnancy	3 (0.1)
Uterine rupture	3 (0,1)
Case fatality rate	34/4203 (0.8)

Pregnancy outcomes, complications and maternal deaths among pregnant and post-partum women with COVID-19

(528, 16.3%) and hypertensive disorders in pregnancy (328, 10.1%). A total of 158 (3.8%) pregnant and post-partum women required intensive care, of which 152 (96%) were due to COVID-19 related complications.

The overall case fatality rate (CFR) in pregnant and post-partum women with COVID-19 was 0.8 per cent (34/4203). Higher CFR was observed in Pune (9/853, 1.1%), Marathwada (4/351, 1.1%) regions as compared to Vidarbha (9/1155, 0.8%), Mumbai Metropolitan (11/1684, 0.7%), and Khandesh (1/160, 0.6%) regions. Comorbidities of anaemia, tuberculosis and diabetes mellitus were associated with maternal deaths.

Website link:

https://www.ijmr.org.in/article.asp?issn=0971-5916;year=2021;volume=153;issue= 5;spage=629;epage=636;aulast=Gajbhiye

NCBS-TIFR studies strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors

Many viruses utilise host endo-lysosomal network for infection, so tracing the endocytic itinerary of SARS-CoV-2 can provide insights into viral trafficking and aid in designing new





Schematics describing experimental protocols for SARS-CoV-2 spike-pseudovirus transduction assay

therapeutic strategies. Here, researchers from InStem demonstrate that the receptor binding domain (RBD) of SARS-CoV-2 spike protein is internalised via the pH-dependent CLIC/GEEC (CG) endocytic pathway in human gastric-adenocarcinoma (AGS) cells expressing undetectable levels of ACE2. Ectopic expression of ACE2 (AGS-ACE2) results in RBD traffic via both CG and clathrin-mediated endocytosis. Endosomal acidification inhibitors like BafilomycinA1 and NH4Cl, which inhibit the CG pathway, reduce the uptake of RBD and impede Spike-pseudoviral infection in both AGS and AGS-ACE2 cells. The inhibition by BafilomycinA1 was found to be distinct from Chloroquine, which neither affects RBD uptake nor alters endosomal pH yet attenuates Spike-pseudovirus entry. By screening a subset of FDA-approved inhibitors for functionality similar to BafilomycinA1, they identified Niclosamide as a SARS-CoV-2 entry inhibitor. Further validation using a clinical isolate of SARS-CoV-2 in AGS-ACE2 and Vero cells confirmed its antiviral effect. Researchers propose that Niclosamide, and other drugs which neutralise endosomal pH as well as inhibit the endocytic uptake, could provide broader applicability in subverting infection of viruses entering host cells via a pH-dependent endocytic pathway.

Website link:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297935/pdf/ppat.1009706.pdf

IIT Bombay studies severity of COVID-19 infection

Researchers from the Indian Institute for Technology Bombay (IIT Bombay) and Kasturba Hospital for Infectious Diseases, Mumbai, led by Prof Sanjeeva Srivastava of IIT Bombay, have found that levels of specific proteins in the nasopharyngeal samples of a person can differentiate



between low and high severity of infection. This information will help hospitals distribute health care resources on time and ensure that those who require critical care can be identified with relative ease.

Contact info:

sanjeeva@iitb.ac.in

Website link:

https://www.iitb.ac.in/en/research-highlight/how-severe-one%E2%80%99s-covid-19-infection

INDUSTRY COLLABORATIONS

3

The information related to contributions from industries, their timely pitching-in and joining the warfare against mitigating the COVID-19 pandemic is provided here to sensitise the larger group of the community.

SECTION GUIDELINES

CSIR-NCL collaborates with industries to manufacture useful moulded plastic components from COVID-19 PPE waste

CSIR-NCL collaborates with industries to manufacture useful moulded plastic components from **COVID-19 PPE** waste

While the COVID-19 pandemic has been raging worldwide, there has been comparatively much less chatter about the associated waste generation from the health care sector. To this effect, Council of Scientific and Industrial Research-National Chemical Laboratory (CSIR-NCL), Pune, jointly with Reliance Industries Ltd (RIL) and several other companies from Pune have managed to manufacture useful six moulded plastic components from COVID-19 PPE waste, as per a press release from the companies.

Ever since the COVID-19 outbreak, there has been a substantial increase in demand for single use plastic items such as PPE, masks, gloves, etc. Across India, more than 200 tons of COVID-19 related waste was generated every day in May 2021. Usually, this hazardous waste is incinerated at central waste management facilities. However, this is not conducive to the environment as incineration is energy-intensive and leads to the release of harmful greenhouse gases, the press release further stated.

CSIR-NCL, RIL and other companies thus tried to develop an end-to-end process for effective recycling of COVID-19 plastic waste to produce plastic products. The focus was on the conversion of suitable plastic waste for downstream processing and identification of potential stakeholders/markets for creating value for entire supply-chain.

In a proof-of-concept study, the CSIR-NCL team successfully demonstrated the lab-scale manufacture of moulded automotive products from the decontaminated PPE plastic waste (at M/s Niky Precision Engineers, Pune) by leveraging the existing recycling infrastructure available in Indian cities.

CSIR-NCL and RIL have now signed an MoU to scale up the production, laying a path to take the concept to the national level. A pilot scale of 100 kg in the Pune city area was successfully implemented by collaborating with Pune-based companies like M/s APPL Industries Limited, M/s SKYi Composites, M/s Harsh Deep Agro Products, M/s Urmila Polymers, M/s Jai Hind Autotech Pvt. Ltd., who produced the recycled goods.

The feed material (PPE kits) was collected and decontaminated by Passco Environmental Solutions, a waste management company located in Pune. CSIR-NCL secured all regulatory approvals needed from the Maharashtra Pollution Control Board (MPCB) to complete this pilot trial.

The technical journey of CSIR-NCL, aided by Reliance and CSIR-Indian Institute of Petroleum (CSIR-IIP) Dehradun, with funding from CSIR, mainly involved converting the decontaminated PPE waste (mainly comprising PPE suits/overalls) into an easily processable and upcycled agglomerated form (pellets or granules).

Website link:

µhttps://www.csir.res.in/sites/default/files/26%20To%2030%20September%202021. pdf



The efforts made by multiple agencies and institutions in compiling the information, releasing the knowledge products in print or digital form, and reaching out to multiple target audiences are gathered here for one point, ready-to-use evidence. These include resource books, newsletters, magazines, exclusive editions, and so on.

SECTION GUIDELINES

IJMR publishes fifth special edition on COVID-19 Ministry of Health & Family Welfare releases guidelines for safe dental practice in the pandemic times CSIR bulletin on COVID-19 news and updates about the pandemic SERB develops COVID-19 diagnostic dashboard – COVID-NIDAN Chikitsa Setu mobile application developed to train doctors, paramedical staff and corona warriors India has achieved milestone of 50 crore COVID-19 sample testing till 18 August MoHFW releases guidelines on operationalisation of maternal health services during the COVID-19 pandemic COVID-19: Science & Technology Efforts in India – An information resource on the pandemic Outreach initiatives through India Science, Technology and Innovation (ISTI) Web Portal Press Information Bureau releases daily bulletin on COVID-19 Government of India presents a regular COVID-19 India factsheet and immunisation programme Outreach initiatives by India Science Channel myGOV reaches out to citizens by inviting blogs for the largest vaccination drive Initiative by myGOV to engage the general public in thanking the healthcare workers

IJMR publishes fifth special edition on COVID-19

The story of COVID-19 pandemic has been continuing unabated for almost a year and a half with numerous unexpected twists and turns due to emerging waves and variants. The pandemic has hit the world severely, including India, especially in the second wave of the pandemic. COVID-19 vaccinations combined with COVID-19 appropriate behaviour are the most effective tools for individual protection and pandemic containment. Extensive risk communications and continued efforts to win public confidence in the vaccine must persist.

The Indian Journal of Medical Research (IJMR) is one of the oldest medical journals in India, as it started in 1913. IJMR publishes peer reviewed quality biomedical research in the form of original research articles, review articles, short papers, and short notes.



Research letters are also published in the corresponding section after peer review. Special issues and supplements are published in addition to the regular issues. In continuation with its tradition of communication, IJMR brings forth the fifth special edition on COVID-19, covering various aspects of the pandemic and the plausibility of any future waves.

Contact info: editorial@ijmr.in Website link: https://www.ijmr.org.in/currentissue.asp?sabs=n

Ministry of Health & Family Welfare releases guidelines for safe dental practice in the pandemic times

In the current COVID-19 pandemic, dentists, auxiliaries as well as patients undergoing dental procedures are at high risk of cross-infection. Most dental procedures require close contact with the patient's oral cavity, saliva, blood, and respiratory tract secretions. Many patients who are asymptomatic may be shedding the virus. Hence all patients visiting a dental clinic must be considered as potential sources of infection and dental professionals must follow appropriate infection prevention control guidelines.

To deal with this situation, the Ministry of Health and Family Welfare (MOHFW), Government of India, issued national guidelines for safe practice during COVID-19. This guideline provides for safe dental practices to be followed in dental clinics located in government and private sector, and dental colleges.

Website link:

https://www.mohfw.gov.in/pdf/ NationalGuidelinesforSafeDentalPracticeDuringCovid19pandemic.pdf

CSIR bulletin on COVID-19 news and updates about the pandemic

CSIR was at the forefront of the battle against COVID-19 pandemic. It also put in place measures to counter the infodemic. *CSIR-In-Media* is a weekly newsletter published by CSIR magazine that showcases the institute's significant research contributions.

Website link:

https://www.csir.res.in/news-bulletin



SERB develops COVID-19 diagnostic dashboard – COVID-NIDAN

Science and Engineering Research Board (SERB), a statutory body of Department of Science & Technology (DST) has developed a dashboard called COVID - National Initiatives on Diagnosis and Analysis Network. The dashboard contains information regarding COVID-19 diagnostic technologies, various researches that are undergoing at various organisations, and other related information.



Contact info: venkatba@serb.gov.in Website link: https://www.covidnidan.in/Covid19/HomePage

Chikitsa Setu mobile application developed to train doctors, paramedical staff and corona warriors

Keeping in view the present COVID-19 pandemic, the Department of Medical Education, Government of Uttar Pradesh has launched an android-based mobile application named Chikitsa Setu for the training of doctors, paramedical staff and other corona warriors in the fight against COVID-19, by providing short, video-based answers to their questions related to coronavirus. This mobile application has been adopted by Uttar Pradesh, Uttarakhand, Jharkhand, Bihar, Chhattisgarh, Punjab, Tamil Nadu and Gujarat.

The key features of the Chikitsa Setu mobile application are:

- I. Videos to train doctors, paramedical staff, safai karmi and other corona warriors
- 2. Contains short duration videos of five minutes



- 3. Bilingual (Hindi and English) application and easy to understand
- 4. User-friendly
- 5. Attractive and intuitive interface
- 6. Highly useful for general public as well
- 7. Includes COVID-19 helpline numbers
- 8. Users can submit their queries
- 9. Contains FAQs and IEC material
- 10. COVID-19 updates (including COVID-19 vaccines) are also available

Website link:

https://www.nhp.gov.in/chikitsa-setu-mobile-application_pg

India has achieved milestone of 50 crore COVID-19 sample testing till 18 August

On 18 August 2021, Indian Council of Medical Research (ICMR), the apex body at the forefront of formulating COVID-19 testing protocols in India, achieved the milestone of conducting 50 crore tests. With average daily testing of more than 17 lakh in August, India has tested 50 crore samples across the country to date. India has achieved the milestone of the last 10 crore tests in only 55 days. On 21 July 2021, India had tested 45 crore COVID-19 samples, which reached the 50 crore mark on 18 August 2021. This has been enabled by rapidly increasing testing infrastructure and capacity across the country.

Contact info:

guptanivedita.hq@icmr.gov.in; sharma.lk@icmr.gov.in

Website link:

https://www.icmr.gov.in/pdf/press_realease_files/ICMR_PressRelease_19082021. pdf

MoHFW releases guidelines on operationalisation of maternal health services during the COVID-19 pandemic

Maternal Health Division, Ministry of Health & Family Welfare (MoHFW) releases guidelines on the operationalisation of maternal health services during the COVID-19 pandemic. This document provides necessary guidance for the management of pregnant women at the community and facility level during the COVID-19 pandemic, including the utilisation of telemedicine for antenatal care services.





e-Sanjeevani online OPD consultation Process

Website link:

https://www.nhm.gov.in/New_Updates_2018/Guidelines_on_Operationalization_ of_Maternal_Health_Services_during_the_Covid-19_Pandemic.pdf

COVID-19: Science & Technology Efforts in India – an information resource on the pandemic

Effective communication is in its own right a nonpharmaceutical intervention for any epidemic that can increase adherence to protective behaviour necessary to mitigate its spread. There is no 'best practice' for communication during a complex public health emergency, but past experiences have led to several principles that contribute to a successful strategy. India is fighting the second wave of the COVID-19 pandemic with a lot of resilience and grit. A very encouraging and precise trend is now visible as the positivity rate is declining rapidly. In 2020, India dealt with the first wave of the COVID-19 pandemic with collective measures, scientific approaches, and awareness. The intelligent use of technology and well-planned resource allocation to tackle the new wave of the pandemic has been dealt with at a war footing. The newsletter – COVID-19: Science & Technology Efforts in India – is being



compiled to inform our readers and strengthen the usefulness of any published information.

To bridge the gap between scientific contributions, leadership and administrative efforts, and the general public's perspective, Vigyan Prasar is continuously reaching out to its audiences by way of a regular e-newsletter, taking its mandate of science communication, popularisation and extension to the next level. Our effort is firmly based on the fact that "science gathers knowledge faster than society gathers wisdom." The steady increase in the number of recoveries and the significant and continuous decrease in positivity rate provide us with the much-needed assurance that this may be the outcome of improving the health infrastructure and making health the cornerstone at the policy level. The e-Newsletter aims to be a handy guide to scientists, researchers, and scholars, especially those interested.



The latest edition was digitally published on 26 September 2021.

Contact info:

covidnewsletter@vigyanprasar.gov.in

Website link:

https://www.indiascienceandtechnology.gov.in/covid-19-the-pandemic/ newsletter-archive

Outreach initiatives through India Science, Technology and Innovation (ISTI) Web Portal

The India Science, Technology and Innovation Portal (ISTI) is a one-stop window for information about developments in India on science, technology, and innovation. The vision is to provide a single-window source of information on a web portal about all data related to the Indian STI ecosystem by aggregating data on scientific inputs and outputs, bringing stakeholders together and disseminating science, technology and innovation content. The portal focuses on bringing all stakeholders and Indian STI activities on a single online platform; helping efficient utilisation of resources; highlighting functioning of scientific organisations, laboratories and institutions; aggregating information on science funding, fellowship and award opportunities spanning from school to faculty level; pooling together conferences, seminars and events; and projecting science in India with its significant achievements. The ISTI web portal has been developed by Vigyan Prasar, an autonomous organisation of the DST.

In the critical times of the outbreak of the COVID-19 pandemic, the web portal serves as a one-stop online information guide to bring together a collection of resources in response to COVID-19. These resources are generated by efforts made by numerous initiatives and schemes taken up by several departments and ministries of the Government of India and numerous institutions spread across the country. The content presented here relies on the best available scientific understanding of the disease and its transmission.

The web portal provides all information related to COVID-19, from presenting symptoms to vaccine science, distribution strategy, and preventive measures initiated for envisaged future waves. It contains content on fact-checks and myth-busters in question and answer format, contributions from the research fraternity, start-up spotlights, industry collaborations, communications and resources, reaching out to society and so on. A dedicated focus has been given to exhibiting funding opportunities catering to the second wave of the COVID-19 pandemic.



Contact info: kdgm@vigyanprasar.gov.in Website link: https://www.indiascienceandtechnology.gov.in/

Press Information Bureau releases daily bulletin on COVID-19

Press Information Bureau (PIB), Government of India releases a daily bulletin on COVID-19, starting from the early days of the COVID-19 outbreak. The bulletin contains press releases concerning COVID-19, issued in the last 24 hours, inputs from PIB field offices, and fact checks undertaken by PIB. These bulletins are published in 14 languages: Hindi, English, Urdu, Marathi, Telugu, Tamil, Punjabi, Bangla, Kannada, Oriya, Gujarati, Assamese, Malayalam and Manipuri. The following data points are released on 05 October 2021.



91.54 Cr. vaccine doses have been administered so far under Nationwide Vaccination Drive
18,346 new cases in the last 24 hours; lowest in 209 days
Active cases account for less than 1% of total cases, currently at 0.75%; Lowest since March 2020
India's Active caseload stands at 2,52,902; lowest in 201 days
Recovery Rate currently at 97.93%; Highest since March 2020
29,639 recoveries in the last 24 hours increases Total Recoveries to 3,31,50,886
Weekly Positivity Rate (1.66%) less than 3% for last 102 days
Daily positivity rate (1.61%) less than 3% for last 36 days
57.53 crore Total Tests conducted so far

Website link:

https://pib.gov.in/PressReleseDetailm.aspx?PRID=1761174

Government of India presents a regular COVID-19 India factsheet and immunisation programme

Government of India has provided, through the free-of-cost category and direct-state procurement category, more than 92 crore vaccine doses (92,17,65,405) to States/UTs.

India's coronavirus cases have crossed three crores, and as of 06 October 2021, 08:00 AM, it stands at 3,38,71,881 cases, of which 3,31,75,656 have recovered. The recovery rate stands at 97.94 per cent while the case fatality rate stands at 1.33 per cent.



Website link: https://www.mygov.in/covid-19

Outreach initiatives by India Science Channel

India Science is an Internet-based Over-The-Top (OTT) science TV channel. It is an initiative of the Department of Science and Technology (DST), Government of India, implemented and managed by Vigyan Prasar (VP), an autonomous organisation of the DST. This 24x7 video platform is dedicated to science and technology knowledge dissemination, with a strong commitment to spreading scientific awareness, especially with Indian perspectives, ethos and cultural milieu. The initiative is supported by the National Council of Science and Technology Communication (NCSTC), DST.

Science and technology are the main driving forces of the nation and fundamental to progress and growth. So, the advantages of science and technology must reach all sections of the society through popular media of communication. India's large Internet user base of 500 million is split between 305 million urban Indians and 195 million rural Indians, all of whom need to be reached with authentic science and technology content. And to do so, the Internet is fast becoming the most accessible and preferred media for content delivery.

Since the occurrence of COVID-19, India Science has been working tirelessly to connect with the people, in the form of regular bulletins, documentaries, interviews, bytes and live sessions of scientists, doctors, experts, science administrators and policymakers. The following is a brief account of the information products produced by India Science.

- I. Weekly COVID-19 video bulletin: Produced in both Hindi and English on a weekly basis from 7 July 2020, COVID-19 bulletin apprises the audience about the latest developments happening in the S&T scenario in India that are helping in managing and overcoming the challenges thrown up by the pandemic. Vigyan Prasar produced a daily COVID-19 bulletin from 11 April to 6 July 2020. Thereafter, a weekly bulletin is being produced, which provides details about the most important S&T updates from the country related to COVID-19. From January 2021 onwards the COVID-19 bulletin carried news about the vaccination drive initiated by the Government of India.
- COVID-19 Explained: Short films to explain the important research findings related to COVID-19 and COVID-19 vaccination in layman's language are produced on a weekly basis. The topics chosen for COVID-19 Explained cater to the curiosity of the common man towards COVID-19.
- 3. Facebook live sessions on interviews of various stakeholders on COVID-19 vaccination programme.
- 4. Facebook and India Science live sessions on interviews with experts on COVID-19 vaccination.
- 5. Live phone in programme: A live phone in programme on COVID-19 vaccination is telecast from India Science on every Monday and Tuesday. Experts from the field give answers to the questions related to COVID-19 vaccination received from the audience.



- India Science started 'Corona Ko Harana Hai' from April 2021. In this programme, India Science team conduct interviews on COVID-19-related different issues with top medical professionals of the country.
- India Science makes infographics on COVID-19-related different issues regularly.
 8. COVID-19 vaccine: Fact File also telecast every Saturday from India Science.



Contact info: kapil@vigyanprasar.gov.in Website link:

https://www.indiascience.in/

myGOV reaches out to citizens by inviting blogs for the largest vaccination drive

myGOV is inviting blogs from Indian citizens for the largest vaccination drive in India. It is inviting citizens from all walks of life to share a blog write-up of 500 words. The topics are as follows:

- I. Overcoming vaccine hesitancy
- 2. Getting Covaxinated (COVID vaccine) is important
- 3. Key to a successful COVID-19 inoculation drive

The blog write-up should be in any of the two formats – word/pdf and the writer should not imprint or watermark the entry. Entries are to be submitted online only. Any other medium/ mode will not be considered for evaluation.



Last date: 31 December 2021

Website link:

https://www.mygov.in/task/inviting-blogs-mygov-citizens-largest-vaccination-drive /?target=inapp&type=task&nid=309211

Initiative by myGOV to engage the general public in thanking the healthcare workers

As the second wave of COVID-19 once again tests India's strength and dedication in defeating coronavirus, doctors, nurses and frontline workers have isolated themselves away from their families and have been working day and night to battle the atrocities of the raging pandemic. To make their job easier and help them, people can support them by following Covid appropriate behaviour and take out time to say a heartfelt thank you.

To make them feel valued, myGOV has started an initiative for healthcare workers, for which you have to first join the Thank You Healthcare Workers Initiative and share your appreciation message.



Last date: 31 December 2021

Website link:

https://www.mygov.in/group-issue/lets-thank-our-healthcareworkers/?target=inapp&type=group_issue&nid=309871

COVID FACT-CHECKS

This section attempts to answer frequently asked questions (FAQs) on various aspects of the COVID-19 disease, variants and mutants, associated illnesses and diseases, riding the second wave, assumptions on future waves, and subsequently busting the myths spread in the society.

SECTION GUIDELINES

- I. SARS-CoV-2 surveillance in India
- 2. Delta and Delta Plus variants
- 3. COVID-19 vaccination for pregnant women
- 4. The third wave of COVID-19 in India and protecting children
- 5. COVID-19 and White Fungus infection
- 6. Related to use of oxygen during current COVID-19 pandemic
- 7. Related to drugs and medications to fight the disease
- 8. Related to Black Fungus and COVID-19 disease
- 9. Related to indoor air and COVID-19 disease

I. SARS-CoV-2 surveillance in India

Q. What is INSACOG?

A. The Indian SARS-CoV-2 Genomics Consortium (INSACOG) is a national multi-agency consortium of Regional Genome Sequencing Laboratories (RGSLs) established by the Government of India on 30 December 2020. Initially, this consortium had 10 laboratories. Subsequently, the scope of laboratories under INSACOG was expanded and at present there are 28 laboratories under this consortium, which monitor the genomic variations in SARS-CoV-2.

Q. What is the objective of INSACOG?

A. The SARS-CoV-2 virus, commonly known as COVID-19 virus posed unprecedented public health challenges globally. To fully understand the spread and evolution of the SARS CoV-2 virus, its mutations and resulting variants, the need for in-depth sequencing and analysis of the genomic data was felt. Against this backdrop, INSACOG was established to expand whole genome sequencing of SARS-CoV-2 virus across the nation, aiding understanding of how the virus spreads and evolves. Any changes to the genetic code, or mutations in the virus, can be observed based on the analysis and sequencing of samples done in the laboratories under INSACOG. INSACOG has the following specific objectives:

- To ascertain the status of variants of interest (VoI) and variants of concern (VoC) in the country
- To establish sentinel surveillance and surge surveillance mechanisms for early detection of genomic variants and assist in formulating effective public health response
- To determine the presence of genomic variants in samples collected during superspreader events and in areas reporting increasing trend of cases/deaths, etc.

Q. When did India start SARS-CoV-2 viral sequencing?

A. India started sequencing SARS-CoV-2 viral sequencing of genomes in 2020. Initially, NIV and ICMR sequenced samples of international passengers who arrived in India from UK, Brazil or South Africa or transited through these countries, as these countries reported a sudden surge in cases. RTPCR positive samples from states reporting sudden surges in cases were sequenced on priority. This was further expanded through the efforts of Council of Scientific and Industrial Research (CSIR), Department of Biotechnology (DBT) and National Centre for Disease Control (NCDC), as well as individual institutions.

The initial focus of India was on restricting the spread of global variants of concern in the country – Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) – which had high transmissibility. The entry of these variants was carefully tracked by INSACOG. Subsequently, the Delta and Delta Plus variants were also identified based on whole genome sequencing analysis conducted in the INSACOG laboratories.

Q. What is the strategy for SARS-CoV-2 surveillance in India?

A. Initially, genomic surveillance was focused on the variants carried by international travellers and their contacts in the community through sequencing three to five per cent of the total RTPCR positive samples.

Subsequently, the sentinel surveillance strategy was also communicated to the States/UTs in April 2021. Under this strategy, multiple sentinel sites are identified to adequately represent the

geographic spread of a region, and RT-PCR positive samples are sent from each sentinel site for whole genome sequencing. Detailed SOPs for sending samples from the identified sentinel sites regularly to the designated RGSLs were shared with States/UTs. The list of INSACOG RGSLs tagged to States was also communicated to the States. A dedicated nodal officer was also designated by all States/UTs for coordinating the activity of whole genome sequencing.

- Sentinel Surveillance (for all States/UTs/): This is an ongoing surveillance activity across India. Each State/UT has identified sentinel sites (including RT-PCR labs and tertiary health care facilities) from where RT-PCR positive samples are sent for whole genome sequencing.
- 2. Surge Surveillance (for districts with COVID-19 clusters or those reporting a surge in cases): A representative number of samples (as per the sampling strategy finalised by a state surveillance officer/central surveillance unit) are collected from the districts, which show a surge in the number of cases and are sent to RGSLs.

Q. What is the standard operating procedure (SOP) for sending samples to INSACOG laboratories?

A. The SOPs for sending samples to INSACOG laboratories and subsequent action based on genome sequencing analysis is as follows:

- 1. The Integrated Disease Surveillance Programme (IDSP) machinery coordinates sample collection and transportation from the districts/sentinel sites to RGSLs. The RGSLs are responsible for genome sequencing and identification of VoCs/Vols, potential Vols, and other mutations. Information on VOCs/ VOIs is submitted to the Central Surveillance Unit, IDSP to establish clinico-epidemiological correlation in coordination with state surveillance officers.
- 2. Based on discussions in the Scientific and Clinical Advisory Group (SCAG) established to support the INSACOG, it was decided that upon identification of a genomic mutation, which could be of public health relevance, RGSL will submit the same to SCAG. SCAG discusses the potential Vols and other mutations and, if felt appropriate, recommends to the Central Surveillance Unit for further investigation.
- 3. The genome sequencing analysis and clinico-epidemiological correlation established by IDSP is shared with MOH&FW, ICMR, DBT, CSIR and States/UTs for formulating and implementing requisite public health measures.
- 4. The new mutations/VoCs are cultured, and genomic studies are undertaken to see the impact on vaccine efficacy and immune escape properties.

Source:

https://dbtindia.gov.in/pressrelease/qa-indian-sars-cov-2-genomics-consortium-insacog

2. Delta and Delta Plus variants

Q. Why are frequent mutations seen in SARS-CoV-2 virus? When will the mutations stop?

A. SARS-CoV-2 can mutate due to the following reasons:

Random error during replication of virus

- Immune pressure faced by the viruses after treatments such as convalescent plasma, vaccination or monoclonal antibodies (antibodies produced by a single clone of cells with identical antibody molecules)
- Uninterrupted transmission due to lack of Covid appropriate behaviour. Here the virus finds an excellent host to grow and becomes more fit and transmissible.

The virus will continue to mutate as long as the pandemic remains. This makes it all the more crucial to follow Covid appropriate behavior.

Q. What are variants of interest (Vols) and variants of concern (VoCs)?

A. When mutations happen – if there is any previous association with any other similar variant, which is felt to have an impact on public health – then it becomes a variant under investigation (Vul).

Once genetic markers are identified, which can have an association with a receptor binding domain or which have an implication on antibodies or neutralising assays, we call them variants of interest (Vols).

The moment we get evidence for increased transmission through field-site and clinical correlations, it becomes a variant of concern (VoC). VoCs are those that have one or more of the following characteristics:

Increased transmissibility

.

- Change in virulence/disease presentation
- Evading diagnostics, drugs and vaccines

The first VoC was announced by the UK where it was found. Currently there are four VoCs identified by the scientists – Alpha, Beta, Gamma and Delta.

Q. What are Delta and Delta Plus variants?

A. These are the names given to variants of SARS-CoV-2 virus, based on the mutations found in them. The World Health Organization (WHO) has recommended using letters of the Greek Alphabet, i.e., Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617), etc., to denote variants, for easier public understanding.

Delta variant, also known as SARS-CoV-2 B.1.617, has about 15-17 mutations. It was first reported in October 2020. More than 60 per cent of cases in Maharashtra in February 2021 pertained to Delta variants.

It is the Indian scientists who identified the Delta variant and submitted it to the global database. The Delta variant is classified as a VoC and has now spread to 80 countries, as per the WHO.

The Delta variant (B.1.617) has three subtypes B1.617.1, B.1.617.2 and B.1.617.3, of which B.1.617.1 and B.1.617.3 have been classified as Vol, while B.1.617.2 (Delta Plus) has been classified as a VoC.

Compared to the Delta variant, the Delta Plus variant has an additional mutation. This mutation is called the K417N mutation. 'Plus' means an additional mutation has happened to the Delta

variant. It does not mean that the Delta Plus variant is more severe or highly transmissible than the Delta variant.

Q. Why has the Delta Plus variant (B.1.617.2) been classified as a VoC?

A. It has been classified as a VoC because of the following characteristics:

- Increased transmissibility
- Stronger binding to receptors of lung cells
- Potential reduction in monoclonal antibody response
- Potential post vaccination immune escape

Q. How often are these mutations studied in India?

A. Indian SARS-CoV-2 Genomics Consortium (INSACOG) coordinated by the Department of Biotechnology (DBT) along with the Union Health Ministry, ICMR, and CSIR monitor the genomic variations in SARS-CoV-2 on a regular basis through a pan India multi-laboratory network. It was set up with 10 national labs in December 2020 and has been expanded to 28 labs and 300 sentinel sites from where genomic samples are collected. The INSACOG hospital network looks at samples and informs INSACOG about the severity, clinical correlation, breakthrough infections and re-infections.

More than 65,000 samples have been taken from states and processed, while nearly 50,000 samples have been analysed of which 50 per cent have been reported to be VoCs.

Q. On what basis are the samples subjected to genome sequencing?

A. Sample selection is done under three broad categories:

- I. International passengers (during the beginning of the pandemic)
- 2. Community surveillance (where RT-PCR samples report CT value less than 25)
- 3. Sentinel surveillance where samples are obtained from labs (to check transmission) and hospitals (to check severity)

When there is any public health impact noticed because of genetic mutation, then the same is monitored.

Q. What is the trend of VoCs circulating in India?

A. As per the latest data, 90 per cent of samples tested have been found to have Delta variants (B.1.617). However, B.1.1.7 strain, which was the most prevalent variant in India in the initial days of the pandemic, has decreased.

Q. Why is action regarding public health not taken immediately after noticing mutations in the virus?

A. It is not possible to say whether the mutations noticed will increase transmission. Also, until there is scientific evidence that proves a correlation between the rising number of cases and

variant proportion, we cannot confirm there is a surge in the particular variant. Once mutations are found, it is analysed every week to find out if there is any such correlation between the surge of cases and variant proportion. Public health action can be taken only if scientific proofs for such correlation are available.

Once such correlation is established, it will help greatly to prepare in advance when such a variant is seen in another area/region.

Q. Do Covishield and Covaxin work against the variants of SARS-CoV-2?

A. Yes, Covishield and Covaxin are both effective against the Alpha, Beta, Gamma and Delta variants. Lab tests to check vaccine effectiveness on Delta Plus variants are ongoing.

Delta Plus variants: The virus has been isolated and is now being cultured at ICMR's National Institute of Virology, Pune. Laboratory tests to check vaccine effectiveness are ongoing and the results will be available in 7 to 10 days. This will be the first result in the world.

Q. What are the public health interventions being carried out to tackle these variants?

A. The public health interventions needed are the same, irrespective of the variants. The following measures are being taken:

- Cluster containment
- Isolation and treatment of cases
- Quarantining of contacts
- Ramping up vaccination

Q. Do public health strategies change as the virus mutates and more variants arise?

A. No, public health prevention strategies do not change with variants.

Q. Why is continuous monitoring of mutations important?

A. Continuous monitoring of mutations is important to track potential vaccine escape, increased transmissibility and disease severity.

Q. What does a common man do to protect self from these VoCs?

A. One must follow Covid appropriate behaviour, which includes wearing a mask properly, washing hands frequently and maintaining social distancing. The second wave is not over yet. It is possible to prevent a big third wave provided individuals and society practice protective behaviour. Further, test positivity rate must be closely monitored by each district. If the test positivity goes above 5 per cent, strict restrictions must be imposed.

Source:

https://pib.gov.in/PressReleseDetailm.aspx?PRID=1730875

3. COVID-19 vaccination for pregnant women

Q. Why is COVID-19 vaccine being recommended for pregnant women?

A. Pregnancy does not increase the risk to COVID-19 infection. Most pregnant women will be asymptomatic or have mild disease, but their health may deteriorate rapidly and that might affect the foetus too. It is important that they take all precautions to protect themselves from COVID-19, including taking the vaccination against the same. It is, therefore, advised that a pregnant woman should take the COVID-19 vaccine.

Q. Who are at higher risk of getting infected with COVID-19?

A. Higher risk of infection involves with:

- A health care worker or a frontline worker
- A community with high or increasing rate of COVID-19 infections
- Those frequently exposed to people outside the household
- Those who have difficulty in complying with social distance if living in a crowded household

Q. How does COVID-19 affect the health of a pregnant woman?

A. Although most (>90 per cent) infected pregnant women recover without hospitalization, rapid deterioration in health may occur in a few. Symptomatic pregnant women appear to be at increased risk of severe disease and death. In severe disease, like all other patients, pregnant women may also need hospitalisation. Pregnant women with underlying medical conditions for example, high blood pressure, diabetes, obesity, age over 35 years are at higher risk of severe illness due to COVID-19.

Q. How does COVID-19 infection of pregnant women affect the baby?

A. Most (over 95 per cent) of newborns of COVID-19 positive mothers have been in good condition at birth. In some cases, COVID-19 infections in pregnancy may increase the possibility of a premature delivery, the baby's weight may be less than 2.5 kg and in rare situations, the baby might die before birth.

Q. Which pregnant women are at a higher risk of developing complications after COVID-19 infection?

A. Pregnant women who are:

- Older than 35 years of age
- Obese
- Have an underlying medical condition such as diabetes or high blood pressure
- Have a history of clotting in the limbs

Q. If a pregnant woman has already had COVID-19, when should she be vaccinated?

A. In case a woman is infected with COVID-19 during the current pregnancy, then she should be vaccinated soon after the delivery.

Q. Are there any side effects of the COVID-19 vaccines that can either harm the pregnant woman or her foetus?

A. The available COVID-19 vaccines are safe and the vaccination protects pregnant women against COVID-19 like other individuals. Like any medicine a vaccine may have side effects, which are normally mild. After getting the vaccine, she can get mild fever, pain at the injection site, or feel unwell for 1-3 days. The long-term adverse effects and safety of the vaccine for the foetus and the child born is not established yet. Very rarely, (one in one to five lakh people) the beneficiary may, after the COVID-19 vaccination, experience some of the following symptoms within 20 days after getting the injection, which may need immediate attention.

Q. When should the vaccine be given to the pregnant woman?

A. The COVID-19 vaccination schedule can be started any time during pregnancy.

Q. What other precautions should the pregnant woman take after vaccination?

A. Counsel the pregnant woman and her family members to continue to practice Covid appropriate behaviour: wearing double masks, frequent hand washing, maintaining physical distance, and avoiding crowded areas, to protect themselves and those around from spreading the COVID-19 infection.

Q. How does a pregnant woman register herself for the Covid-19 vaccination?

A. All pregnant women need to register themselves on the Co-WIN portal or may get themselves registered on-site at the COVID-19 vaccination centre. The process of registration for pregnant women remains the same as of the general population and as per the latest guidelines provided by the Ministry of Home and Family Welfare (MoHFW) from time to time.

Source:

https://www.mohfw.gov.in/pdf/ OperationalGuidanceforCOVIDI9vaccinationofPregnantWoman.pdf

4. The third wave of COVID-19 in India and protecting children

Q. What is the possibility of a third wave of COVID-19 in the coming months?

A. Pandemics are likely to occur in multiple waves, and each wave could vary in the number of cases and its duration. Eventually, most of the population may get immune by asymptomatic or symptomatic infections (herd immunity). Over time, the disease may die out or may become endemic in the community with low transmission rates.

Key Message: There is a possibility of a third wave, but it is difficult to predict its timing and severity.

Q. Are children at greater risk if the third wave strikes?

A. In the first wave, primarily the elderly and individuals with co-morbidities were affected with severe disease. In the current (second) wave, a large number of younger population (30-45 years) have developed severe disease as also those without co-morbidities. After the second

wave is over, if we do not continue following COVID appropriate behaviour, the third wave, if it occurs, is likely to infect the remaining non-immune individuals and that may include children also. The latest sero survey (December 2020 to January 2021) showed that the percentage of infected children in the age group of 10-17 years was around 25 per cent, the same as adults. This indicates that while children are being infected like adults, they are not getting the severe disease.

Key Message: Children are as susceptible as adults and older individuals to develop an infection but not a severe disease. It is highly unlikely that the third wave will predominantly or exclusively affect children.

Q. Are children likely to suffer from severe disease as being witnessed in the adult population in the current wave?

A. Fortunately, children have been relatively less affected so far due to several factors. The most important reason is the lesser expression of specific receptors to which this virus binds to enter the host and also the immune system of the children. A very small percentage of infected children may develop moderate to severe disease. If there is a massive increase in the overall numbers of infected individuals, a larger number of children with moderate to severe disease may be seen. Apart from the infection, parents should watch out for mental health issues in children and keep a watch to prevent child abuse and violence. Also, it is worth limiting screen time and prepare children for safe school reopening as per the Indian Academy of Pediatrics (IAP) guidelines.

Key Message: Almost 90 per cent of the infections in children are mild/asymptomatic. Therefore, the incidence of severe disease is not high in children.

Q. Can we rule out the possibility of severe infections in children in the third wave?

A. As explained, the spectrum of illness is likely to be much less severe in children than adults; there is only a remote possibility of children being more severely affected than adults in the next wave. As per data collected during the first and second waves, severe COVID-19 infections in children were not reported and only in few cases they were admitted to ICU. However, we need to be watchful about how the mutant strains will behave. The dictum here is better be ready and prepared for the worst and hope for the best!

Key Message: Severe COVID-19 cases in children are rare. Further, there is no evidence indicating that children will have severe disease in the third wave.

Q. Severe disease due to COVID-19 is already occurring in children. Why it is so?

A. Yes, a severe illness related to COVID-19 is known to occur in children. This includes pneumonia and Multisystem inflammatory syndrome in children (MIS-C). However, COVID-19 pneumonia in children is uncommon as compared to adults. In some cases, after 2-6 weeks of asymptomatic or symptomatic COVID-19 infection, MIS-C may be seen due to immune dysregulation with the incidence of 1-2 cases per 100,000 population; some of these cases also may be severe. It's a treatable condition with a good outcome if diagnosed early. Also, most children suffering from MIS-C cannot transmit the infection to others.

Key Message: Children occasionally get the severe disease and may need ICU care, both during the acute illness and after 2-6 weeks due to MIS-C caused by COVID-19. But the majority are likely to recover if treated on time.

Q. What preparations are being made in case the third wave comes and affects the children?

A. Most affected children get a mild disease with fever and need supervised home care with monitoring. We have learned a lot about COVID-19 illness from our shared experiences in adult medicine in the last 15 months. IAP guidelines on the management of COVID-19 in children are in place, and paediatricians have been sensitised and trained on its management. We need to be ready for a more significant number of patients seeking consultations; educating the parents on different platforms regarding illness and warning signs; and arranging more COVID-19 wards for children with more special wards such as high-dependency units (HDU) and intensive care units (ICU). The preventive behaviours are the same for children. Parents should also be ideal role models for their children regarding mask etiquette, hand hygiene, and social distancing. Children above the age of two to five years can be trained to use a mask; however, the adults have to follow the COVID-appropriate behaviour. IAP has also set guidelines for the safe reopening of schools for the safety of the children.

Key Message: We need to be prepared with more in-patient beds and intensive care beds for children. IAP has already developed the management protocol for disease categories in children. There is no reason to panic. Our preparations are in full swing.

Q. What is the plan for vaccinating children?

A. So far, the global data show that compared to children, older adults are a thousand times more likely to die from COVID-19 disease. So, it has been a priority to vaccinate the high-risk elderly age group first. Thereafter, the emphasis should be on adults who also have more severe diseases as compared to children. When there is the remote possibility of children getting affected, some countries consider vaccinating children and adolescents. The same vaccines being used in adults can be used in children only after adequate trials. One of the India-made vaccines will soon undergo trials in children, and if proven immunogenic and safe, it could be fast-tracked for mass vaccination in children.

Key Message: Children do get the severe disease, even if the number is small. Thus, there is no harm in considering vaccination for them. The safety and efficacy, however, are being assessed in trials for this age. The national expert group on vaccine administration for COVID-19 will develop a plan as and when new scientific data emerge.

Source

https://iapindia.org/pdf/hA5Gnpt_IQv63Bk_IAP%20view%20point%20for%20 3rd%20wave%20Covid%2022%20May%202021.pdf

5. COVID-19 and White Fungus infection

Q. What is White Fungus?

A. White Fungus, also known as candidiasis, is an opportunistic infection, which could spread fast to various body parts and if not treated could be serious. According to the Centre for Diseases Control and Prevention (CDC), White Fungus or invasive candidiasis can affect the blood, heart, brain, eyes, bones, or other parts of the body.

Q. Who are at high risk to get White Fungus infection?

A. White Fungus is all around us as it is found naturally in the environment. It primarily affects people with low immunity, who come in contact with objects that contain these fungal spores.



For instance, COVID-19 patients on oxygen support can come in contact with these fungal spores if their ventilators and oxygen support equipment are not sanitised properly. Further, overuse of steroids and use of tap water in the humidifier attached to an oxygen cylinder can also heighten the risk of contracting White Fungus.

Q. Who can get infected by white fungus?

A. Invasive candidiasis is caused by a yeast (a type of fungus) called Candida. Candida can normally live inside the body, in areas like the mouth, throat, gut, and vagina, without causing any problems. However, individuals with low immunity, like patients recovering from a serious COVID-19 infection, are particularly at risk of contracting this fungal infection. In their bodies, the fungus can enter the bloodstream or internal organs to cause an infection.

People who are at high risk for developing this infection include those who:

- Have been admitted in the intensive care unit (ICU) for a prolonged period.
- Have weakened immune system (for example, people on cancer chemotherapy, people who have had an organ transplant, and people with low white blood cell counts).
- Have recently had surgery, especially multiple abdominal surgeries.
- Have recently received lots of antibiotics or steroids in the hospital.
- Receive total parenteral nutrition (food through a vein).
- Have kidney failure or are on hemodialysis.
- Have diabetes.
- Have a central venous catheter.

Q. Is White Fungus contagious?

A. White Fungus is not contagious in most cases, as it cannot spread directly from person to person. However, there exist some species of fungus that cause this infection on the skin. In such instances of external infection, the fungus can possibly be transferred from the patient to another individual who is at risk.

Q. What are the symptoms of White Fungus?

A. Only CT scans or X-rays can reveal and completely confirm the White Fungus infection. Health experts report that it is more dangerous than Black Fungus, as it affects the lungs as well as other parts of the body like the nails, skin, stomach, kidney, brain, private areas, and mouth.

Moreover, the White Fungus can also infect the lungs the same way COVID-19 does. In fact, patients who get infected with White Fungus displayed COVID-19-like symptoms despite having tested negative for the virus. According to some reports, the oxygen saturation level of one of the four patients infected with White Fungus dropped from normal levels. However, the oxygen levels became normal after the antifungal medication was administered.

Q. How can White Fungus be treated?

A. Patients infected with White Fungus should be examined carefully, perhaps with a fungus culture test of their phlegm or mucus, to detect the extent of fungal infection in their body. After detection of the infection, antifungal medications can be used to treat the patients. Such medications have led to an improvement in their condition. The type and dose of antifungal medication used to treat White Fungus will depend on the patient's age, immune status, location, and severity of the infection.



6. Related to use of oxygen during current COVID-19 pandemic

Q. What is the normal respiratory rate of a healthy adult person?

A. Standard respiratory rates for a healthy adult range from 12 to 20 breaths per minute.

Q. Are 8 breaths per minute normal?

A. No. A patient needs to be evaluated medically.

Q. How many litres of oxygen per minute do we breathe?

A. The average tidal volume, i.e., the average amount of air inhaled and exhaled per breathing cycle, is 0.5 litre (500 ml). Minute ventilation (VE) is the total volume of air entering the lungs in a minute, which is 6 litres per minute.

Q. What should be the normal oxygen saturation as recorded by a Pulse Oximeter?

A. The normal oxygen saturation level in the blood (SpO_2) should be 95 per cent or higher. Some people with chronic lung disease, such as Chronic Obstructive Pulmonary Disease (COPD) or sleep apnea, may have normal levels of around 90 per cent. The 'SpO₂' reading on a pulse oximeter shows the percentage of oxygen in the blood. If your home SpO₂ reading is lower than 94 per cent, call your health care provider.

Q. How do I check my oxygen level at home without a Pulse Oximeter?

A. If you do not have a portable finger pulse oximeter in your home, you can also learn how to assess signs and symptoms of low oxygen levels. Two classic signs of a low oxygen level are a rapid heart rate and a fast breathing rate. An average heart rate is 60–100 beats per minute and an average breathing rate is 12–20 breaths per minute. However, under low oxygen conditions, body responses include an increase in heart rate and breathing rate. Another sign of a low blood oxygen level is cyanosis or a bluish colour change on your lips, nose, or fingertips. As your body loses oxygen, the blood cells in your body change colour in your bloodstream to a dark blue, which can be seen from the outside of your skin if it is severe. Cyanosis is typically a late sign of low oxygen levels and is considered a medical emergency. If you notice this bluish discolouration, you should immediately visit the nearest hospital.

Q. Do we see many cases of silent hypoxia in this wave? How can this be addressed?

A. Silent hypoxia or happy hypoxia is referred to as the early stage of COVID-19. As the oxygen level drops, one may start feeling shortness of breath, confusion, and other symptoms. Keep watching for these signs and do not ignore them. This is true for young people as well. If you monitor low oxygen level, change in lip colour from natural to blue or persistent sweating, consult the covid helpline or doctor. They could be the early sign of silent hypoxia.

Q. In brief, how can proning help enhance blood oxygen levels?

A. Proning is a medically accepted process to improve the distribution and exchange of oxygen in the lungs. A patient is safely placed from their back onto their abdomen (stomach), i.e., face



down to improve breathing and oxygenation. It has been shown as beneficial for COVID-19 patients with compromised breathing comfort, especially during home isolation.

Q. Is pure oxygen used in hospitals?

A. Medical oxygen contains high purity oxygen used for medical treatments and is developed for use in human body. Cylinders contain a compressed oxygen gas and no gases are allowed in the cylinder to prevent contamination.

Q. What is the use of medical oxygen?

A. Oxygen is used for treatment in hospitals. Hence, it is considered a drug or a pharmaceutical product.

Q. What is the need for medical oxygen?

A. The human body requires oxygen to survive, and typically, we breathe in from air. However, if you have lung disease or other medical conditions such as COVID-19, you may not get enough oxygen due to compromised lungs. That can leave you short of breath and cause problems with your heart, brain, and other parts of your body.

Q. Can breathing 100 per cent oxygen harm your body?

A. Yes. Breathing 100 per cent oxygen also eventually leads to collapse of the alveoli (atelectasis).

Q. Can you get excess (more than required) oxygen from an oxygen concentrator?

A. It is possible to get excess (more than required) oxygen from an oxygen concentrator. However, this is quite rare when oxygen concentrators are used as directed and prescribed. All supplemental oxygen requires a prescription from a doctor, who carefully chooses your oxygen requirement.

Q. What is the role of oxygen during COVID-19 disease?

A. The demand for medical oxygen increases in COVID-19 as the disease primarily affects the lungs and, in severe cases, causes death due to Acute Respiratory Distress Syndrome (ARDS) and pneumonia.

Q. When does a patient require medical oxygen in a COVID-19 positive case?

A. As per AIIMS/ICMR-Covid-19/National Task Force/Joint Monitoring Group (Dte.GHS), MoHFW, Government of India, Clinical Guidelines for Management of Adult COVID-19 Patient issued on 22 April 2021, moderate and severe cases of COVID-19 where the infection induces shortage of oxygen in the body due to its impact on lungs require medical oxygen and immediate oxygen therapy. Oxygen acts as a life-saver for COVID-19 patients.

Q. What is moderate COVID-19 cases?

A. In moderate COVID-19 cases a patient has upper respiratory tract symptoms (and/or fever) with shortness of breath. They have a respiration rate more than or equal to 24/minute and SpO_2 90 per cent to 93 per cent with ambient air.

Q. What is severe COVID-19 cases?

A. In severe Covid-19 case, a patient has upper respiratory tract symptoms (and/or fever) with shortness of breath. They have a respiration rate more than 30/minute and SpO₂ less than 90 per cent in room air.

Q. When does a patient require mechanical ventilator support?

A. A patient may be put on a mechanical ventilator if it becomes very difficult to breathe or get enough oxygen into their blood. This condition is called respiratory failure. Mechanical ventilators are machines that act as bellows to move air in and out of the patient's lungs. The respiratory therapist and doctor sets the ventilator to control how often it pushes air into the lungs and how much air the patient gets. The patient may be fitted with a mask to get air from the ventilator into there lungs. Or they may need a breathing tube if their breathing problem is more serious.

Q. Can mechanical ventilation be given at home?

A. Mechanical ventilators are mainly used in hospitals and transport systems such as ambulances and medical evacuation by air transport, etc. In some cases, they can be used at home if the illness is long-term and the caregivers at home receive training and have adequate nursing and other resources at home. Being on a ventilator may make a patient more susceptible to pneumonia, damage to the vocal cords, or other problems.

Q. What is the six minute walk test for COPD?

A. The six minute walk test (6MWT) is an exercise test that measures functional status in chronic obstructive pulmonary disease (COPD) patients and provides information on oxygen desaturation. This test is also being used for COVID-19. In case of COVID-19 symptoms, SpO_2 level must be checked before taking a walk. Now, walk for six minutes without a break on an even surface and measure the SpO_2 level. It may fall 1-2 per cent, but consult a medical professional if it falls below 93 per cent.

Source:

https://ndma.gov.in/sites/default/files/2021-03/FAQs-on-Use-of-oxygen-.pdf

7. Related to drugs and medications to fight the disease

Q. Is Remdesivir effective in the treatment of COVID-19?

A. No study has conclusively been able to prove that Remdesivir is beneficial in the treatment of COVID-19. However, India has approved Remdesivir under the National Clinical Management Protocol for COVID-19, which was developed after many interactions by a committee of experts. The protocol acts as the guiding document for the treatment of COVID-19 patients in India. Remdesivir is listed as an investigational therapy in the protocol, i.e., where informed and shared decision-making is essential, besides noting contraindications mentioned in the detailed guidelines.

Q. What is Remdesivir? How does Remdesivir work?

A. Remdesivir is an investigational drug used to treat viral infections. It is classified as a broad-spectrum antiviral with potential antiviral activity against a variety of RNA viruses.



The drug works against the novel coronavirus by inhibiting replication of the virus in the body. Remdesivir functions as a pro-drug that is modified in the body before it becomes an active drug. It is classified as a nucleoside analog, one of the oldest classes of antiviral medications, and resembles the RNA base adenosine. In general, nucleoside and nucleotide analogues simulate the structure of a true nucleoside or nucleotide. The simulated structure may then be incorporated into the virus. Remdesivir works when the enzyme replicating the genetic material for the novel coronavirus – RNA polymerase – incorporates the adenosine analogue in place of the natural molecule into the growing RNA strand. By introducing the modified agent, Remdesivir, replication of the novel coronavirus is interrupted, and the virus ceases to multiply and cannot infect more cells in the body.

Q. When should a patient of COVID-19 take Remdesivir?

A. The timing of the drug, when it is administered, is most important. Taking it too early or too late could do more harm than good. Remdesivir is applicable only in hospitalised patients who showed very low oxygen saturation and infiltrated their chest X-ray or CT scan. The optimal timing for Remdesivir is usually after five to seven days of having the virus. Early to mild or asymptomatic patients should not take Remdesivir. Also, it is of no use if it's given very late because it would create a cytokine storm. A cytokine storm is when the immune system goes into overdrive. The body starts to attack its cells and tissues instead of just the virus.

Q. Can Remdesivir be taken at home?

A. Remdesivir comes in a vial and has to be injected only after prescription and in the presence of a health practitioner. It is for patients who are hospitalised and severe. Therefore, it should not be given at home. It is for patients who need to be admitted and need hospital care.

Q. Are steroids effective in the treatment of COVID-19?

A. There is no evidence to support the use of steroids in the treatment of COVID-19. World Health Organization (WHO) recovery trial showed that steroids do have a beneficial effect. But again, the timing is critical. The recovery trial clearly showed that if we give steroids too early, it showed a harmful effect before oxygen saturation. Steroids are most effective during the later part of the disease when there is more inflammation and oxygen saturation is falling. Steroids are only helpful for moderate or severe cases.

Q. Is plasma a good way to fight off COVID-19?

A. Convalescent plasma has been a therapy devised to passively transfer antibodies from a recovered person to a new patient. While the therapy has been received with different opinions by the medical community, the important aspect is timing. It's better if plasma therapy is used early before clinical worsening. Also, plasma with high titer neutralising antibodies would have better results. Hence, to achieve good results, correct patient selection, timing and a good quality plasma donor are needed for success in this form of treatment.

Q. Should a person with COVID-19 take Tocilizumab?

A. Tocilizumab is a drug of last resort. It should only be used when a COVID-19 infection in a patient is worsening despite steroids, Remdesivir and other treatments like anticoagulants. Tocilizumab is required in less than 2 per cent of COVID-19 patients. Very few patients need this drug because it's only for treating a cytokine storm and has a limited role.



Q. Is Favipiravir effective in treating COVID-19?

A. Favipiravir is another antiviral that is being promoted for the treatment of COVID-19. It was initially doled out as a treatment of influenza after the H1N1 pandemic. There is not enough evidence in robust studies to show that it is a good drug. Since it's not a proven treatment, India's national guidelines also don't recommend its use.

Q. Is it possible to treat COVID-19 without any of the drugs mentioned above?

A. People with mild COVID-19 or those who are asymptomatic will improve with just symptomatic treatment. Mild COVID-19 infection can be treated with paracetamol, good hydration and multivitamins – without any treatment. Giving treatment when it is not required may be doing more harm than good.

8. Related to Black Fungus and COVID-19 disease

Q. What is Black Fungus?

A. Black Fungus, also known as mucormycosis, is a rare fungal infection. It is called 'black' because of the colour of the fungal growth. It is caused by exposure to mucor mold found in soil, manure, and rotten/decaying fruits and vegetables. It is ubiquitous and even present in the nose/mucosa of healthy individuals. This disease usually affects the sinuses, eye orbit, and brain. That is why it is also called 'rhino-orbital-cerebral' mucormycosis. It may be life-threatening in immuno-compromised individuals (cancer patients, HIV/AIDS) and people with uncontrolled diabetes.

Q. What are the risk factors for acquiring Black Fungus infection?

- A. Risk Factors are:
- Uncontrolled Diabetes Mellitus
- Treated for COVID-19 with corticosteroids
- Treated for COVID-19 with immunomodulators
- Treated for COVID-19 with mechanical ventilation
- Prolonged oxygen therapy
- Prolonged ICU stay
- Immuno-compromised state

Q. Why the sudden increase in Black Fungus cases?

A. It may be triggered by extensive use of steroids, which is a life-saving treatment for moderate to severe COVID-19 infection. Steroids lower the immunity and cause a sudden up-shooting of blood sugar levels in diabetes and non-diabetic patients. For patients on humidified oxygen, care should be taken to make sure there is no water leak to prevent the growth of the fungus.

Q. How serious is Black Fungus?

A. Black fungus infection causes a vision-threatening and life-threatening condition.

Q. Do all COVID-19 patients need to be worried about Black Fungus infection?

A. No. As discussed, high-risk patients need to be alert. Also, during COVID-19 recovery, everyone should watch out for early signs and symptoms.

Q. What are the precautions one can take to avoid this disease?

A. One can take the following precautions:

- Boost immune system with diet, hydration and exercise.
- Rational use of steroids by follow guidelines.
- Strict blood sugar monitoring and control in all patients who are on steroids.

Q. What are the early signs of Black Fungus?

A. Some of the early signs are:

- Facial pain
- Facial swelling/puffiness/discolouration
- Sinus headache
- Stuffy nose
- The blurring of vision/decreased vision
- Double vision
- Drooping of eyelid
- Blood-stained nasal discharge
- Dental pain

Q. Is Black Fungus treatable?

A. Yes. Early diagnosis and a prompt multi-speciality team of medical professionals can manage it.

Q. Which specialist should I visit for Black Fungus?

A. ENT and eye specialists are central to this disease. The team includes care coordination with neurosurgeon, endocrinologist and microbiologist.

Source:

https://www.eyeqindia.com/frequently-asked-questions-on-covid-and-blackfungus/#toggle-id-9

9. Related to indoor air and COVID-19 disease

Q. Will running an evaporative cooler help protect my family and me from COVID-19?

A. Evaporative coolers (or 'swamp coolers') can help protect people indoors from the airborne transmission of COVID-19 because they increase ventilation with outside air to cool indoor spaces. Evaporative coolers are used in dry climates. They use water to provide cooling and improve relative humidity in indoor microenvironments. When operating as intended (with open windows), these devices produce substantial increases in ventilation with outdoor air. Some evaporative coolers can be performed without using water when temperatures are milder to increase ventilation indoors. Avoid using evaporative coolers if air pollution outside is high and the system does not have a high-efficiency filter.

Q. Is ventilation important for indoor air quality when cleaning and/or sanitising for COVID-19 indoors?

A. When cleaning and disinfecting for COVID-19, ventilation is essential – in general, increasing ventilation during and after cleaning help to reduce exposure to cleaning and disinfection products and by-products. Increasing ventilation, for example, by opening windows or doors, can also reduce risks from particles resuspended during cleaning, including those potentially carrying SARS-CoV-2 (or other contaminants). Avoid ventilation with outdoor air when outdoor air pollution is high or when it makes your home too cold, hot, or humid.

Q. Will an air cleaner or air purifier help protect my family and me from COVID-19 in my home?

A. When appropriately used, air purifiers can help reduce airborne contaminants, including viruses, in a home or confined space.

Q. How can I increase ventilation at home to help protect my family from COVID-19?

A. Ensuring proper ventilation with outside air is a standard best practice for improving indoor air quality. To increase ventilation in your home, one can:

- Open the windows or screened doors, if possible;
- Operate an air conditioner that has an outdoor air intake or vent; and
- Operate a bathroom fan when the bathroom is in use and continuously, if possible.

However, the practices mentioned here are not enough to protect people from COVID-19. When used along with other best practices recommended by the Ministry of Health and Family Welfare, Government of India, the above methods can be part of a plan to protect yourself and your family.

Source:

https://www.epa.gov/coronavirus/indoor-air-and-coronavirus-covid-19

FEEDBACK FORM



It has been more than a year since the COVID e-Newsletter started reaching you and we want to hear what you think about it. The information product is designed to keep you conversant about the services and efforts the country has put up on the face of the sudden eruption of the COVID-19 pandemic. Your opinion is vital so that we can make sure we are including what you want to read. Please fill in the form below and rest assured that the information you give will help shape future editions of your coveted newsletter.

I. How do you rate the following aspects of COVID e-Newsletter, focused on the second wave of the pandemic?

- 1. The overall appearance
- 😉 Very Good 😊 Good 😑 Average 🙁 Poor 😞 Very Poor 🙂 No Opinion
- 2. Ease to read and flow of information
- Servery easy Serverse asy Se



For suggestions and feedback, click on: https://www.indiascienceandtechnology.gov.in/covid-newsletter/feedback-form



Science & Technology Efforts in India

VOL. IV ISSUE 12 11TH OCTOBER 2021

TOGETHER WE CAN AND WE WILL BEAT THE PANDEMIC OUT

For suggestions and feedback, write to us at: covidnewsletter@vigyanprasar.gov.in



VIGYAN PRASAR A-50, Institutional Area, Sector-62 NOIDA 201 309 (Uttar Pradesh), India Phones: 0120-240 4430-35 Fax: 91-120-240 4437 E-mail: info@vigyanprasar.gov.in